Patents by Inventor Pei Huo

Pei Huo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220399379
    Abstract: A driving backplane includes: a base; a first conductive layer disposed on the base, the first conductive layer including at least one first signal line; a first insulating layer disposed on a side of the first conductive layer away from the base; a second conductive layer disposed on a side of the first insulating layer away from the first conductive layer, the second conductive layer including at least one second signal line. Each first signal line and a second signal line constitute a signal line pair. In the signal line pair, extending directions of the first signal line and the second signal line are the same, an orthogonal projection of the first signal line on the base and an orthogonal projection of the second signal line on the base have a first overlapping region, and the second signal line is coupled to the first signal line.
    Type: Application
    Filed: December 18, 2020
    Publication date: December 15, 2022
    Applicants: Chongqing BOE Display Technology Co.,Ltd., BOE TECHNOLOGY GROUP CO., LTD.
    Inventors: Wentao WANG, Dawei SHI, Pei WANG, Dongsheng ZHAO, Lu YANG, Liang HUO, Cenhong DUAN, Can HUANG, Xiaosong WEN
  • Publication number: 20220273770
    Abstract: Glucose-responsive insulin conjugates that contain one or more trisaccharides are provided. Such insulin conjugates may display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose, even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule.
    Type: Application
    Filed: July 23, 2020
    Publication date: September 1, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Danqing Feng, Erin N. Guidry, Pei Huo, Andrew J. Kassick, Ahmet Kekec, Songnian Lin, Christopher R. Moyes, Dmitri A. Pissarnitski, Lin Yan, Yuping Zhu
  • Patent number: 11058775
    Abstract: Insulin dimers conjugated to peptides having at least one incretin activity are disclosed.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: July 13, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Anandan Palani, Zhiqiang Yang, Lin Yan, Songnian Lin, Pei Huo, Ravi Nargund
  • Publication number: 20210198339
    Abstract: The present disclosure provides conjugates that comprise an insulin molecule conjugated via a conjugate framework to two or more separate ligands that each include a saccharide, wherein the framework, ligand, saccharide and insulin molecule optionally comprise a fatty chain (e.g., a C8-30 fatty chain), wherein when said insulin molecule is conjugated both to a C8-30 fatty chain and one or more separate ligands that each include a saccharide, said C8-30 fatty chain is linked to insulin molecule only, and wherein when the framework or ligand comprises a fatty chain the insulin molecule is conjugated to two or more separate ligands. In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile.
    Type: Application
    Filed: December 13, 2018
    Publication date: July 1, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Lin Yan, Pei Huo, Ahmet Kekec, Danqing D. Feng, Yuping Zhu, Dmitri Pissarnitski, Chris Moyes, Songnian Lin
  • Patent number: 11041009
    Abstract: An insulin conjugate comprising or consisting of a tri-valent sugar cluster is described. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: June 22, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Danqing Feng, Pei Huo, Ahmet Kekec, Songnian Lin, Christopher R. Moyes, Ravi Nargund, Brenda Pipik, Dmitri A. Pissarnitski, Lin Yan, Yuping Zhu
  • Publication number: 20210177981
    Abstract: The present disclosure provides conjugates which comprise an insulin molecule conjugated via a conjugate framework to one or more separate ligands that include a first saccharide, and wherein the conjugate framework also comprises a fatty chain (e.g., a C8-30 fatty chain). In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.
    Type: Application
    Filed: December 13, 2018
    Publication date: June 17, 2021
    Applicants: Merck Sharp & Dohme Corp., SmartCells, Inc.
    Inventors: Lin Yan, Pei Huo, Ahmet Kekec, Yuping Zhu, Dmitri Pissarnitski, Danqing D. Feng, Chris Moyes, Zhiqiang Zhao, David N. Hunter, Songnian Lin, Thomas M. Lancaster, Benjamin Chen
  • Patent number: 10800827
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: October 13, 2020
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • Patent number: 10689430
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: June 23, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Christina Madsen-Duggan, Yuping Zhu, Ahmet Kekec, Zhicai Wu
  • Publication number: 20200087375
    Abstract: An insulin conjugate comprising or consisting of a tri-valent sugar cluster is described. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.
    Type: Application
    Filed: March 19, 2018
    Publication date: March 19, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Danqing Feng, David N. Hunter, Pei Huo, Ahmet Kekec, Songnian Lin, Christopher R. Moyes, Ravi Nargund, Brenda Pipik, Dmitri A. Pissarnitski, Lin Yan, Zhiqiang Zhao, Yuping Zhu
  • Publication number: 20190192675
    Abstract: Insulin dimers conjugated to peptides having at least one incretin activity are disclosed.
    Type: Application
    Filed: April 21, 2017
    Publication date: June 27, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Anandan PALANI, ZhiQiang YANG, Lin YAN, Songnian LIN, Pei HUO, Ravi NARGUND
  • Publication number: 20190175744
    Abstract: Insulin-incretin conjugates comprising a peptide having agonist activity at the glucagon-like 1 (GLP-1) receptor, the glucagon (GCG) receptor, and/or the gastric inhibitory protein (GIP) receptor conjugated to an insulin molecule having agonist activity at the insulin receptor and use of the conjugates for treatment of metabolic diseases, for example, Type 2 diabetes, are described.
    Type: Application
    Filed: March 13, 2017
    Publication date: June 13, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Anandan Palani, Chunhui Huang, Zhiqiang Yang, Lin Yan, Songnian Lin, Pei Huo, Qiaolin Deng, Elisabetta Bianchi, Federica Orvieto
  • Publication number: 20190177393
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Application
    Filed: May 23, 2017
    Publication date: June 13, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Christina Madsen-Duggan, Yuping Zhu, Ahmet Kekec, Zhicai Wu
  • Publication number: 20190092833
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Application
    Filed: November 26, 2018
    Publication date: March 28, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • Patent number: 10183981
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: January 22, 2019
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • Publication number: 20180291078
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 11, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • Patent number: 10017556
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: July 10, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • Publication number: 20180110863
    Abstract: Insulin conjugates comprising an insulin analog molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein the saccharide for at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.
    Type: Application
    Filed: April 4, 2016
    Publication date: April 26, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Danqing Feng, Erin N. Guidry, Pei Huo, Niels C. Kaarsholm, Songnian Lin, Ravi P. Nargund, Lin Yan
  • Patent number: 9889205
    Abstract: Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein the saccharide for at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: February 13, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo
  • Publication number: 20170355743
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Application
    Filed: November 19, 2015
    Publication date: December 14, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • Publication number: 20170107268
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Application
    Filed: November 19, 2015
    Publication date: April 20, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu